Eli Lilly and Co. took another step toward adding a way for patients to hang onto their weight loss when the firm disclosed positive top-line data from the phase III Attain-Maintain trial with orforglipron, a once-daily oral small molecule GLP-1 receptor agonist. Indianapolis-based Lilly said that at one year orforglipron met the primary and all key secondary endpoints vs. placebo, delivering superior weight maintenance as an adjunct to a healthy diet and physical activity, using the efficacy estimand and modified treatment-regimen estimand. Read More

Insilico Medicine Inc. plans to raise HK$2.27 billion (US$292 million) in its IPO on the Hong Kong Securities Exchange to advance its clinical pipeline and invest further in generative AI and automated laboratories. Read More

Rznomics Inc. continued South Korea’s year-end biotech rally with a ₩46.35 billion (US$31.35 million) IPO Dec. 18. Proceeds will fund Seongnam-si, South Korea-based Rznomic’s pipeline of gene therapies, built on the company’s trans-splicing ribozyme RNA Replacement Enzyme technology platform. Read More

The BioWorld Biopharmaceutical Index extended its autumn rally after a more modest September, finishing November up 23.41% for the year. The gain lagged the Nasdaq Biotechnology Index, which surged 34.97% in the first 11 months of the year, but outpaced the broader Dow Jones Industrial Average, which rose 12.16% in the same period. Read More

Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their blood. Yet that reality is limited to those with access to treatment. More than 40 million people worldwide live with HIV, with over a million new infections and hundreds of thousands of deaths each year, underscoring that major challenges remain. Read More

New hires and promotions in the biopharma industry, including: Bavarian Nordic, CNS, Cytoagents, Nanology, Topadur. Read More

Biopharmas raising money in public or private financings, including: Alvotech, Fibrobiologics, Immunome, Kodiak, Kyverna, Maia, T-Curx. Read More

Clinical updates, including data readouts and publications: 4D, Astellas, Avacta, Galderma, Hansa, Immunity, IO Biotech, Merck & Co., Nature Cell, Nektar, Oncolytics, Pfizer, Processa, SAB, Sol-Gel, Soligenix, Thryv, Traws, Vistagen. Read More

Biopharma happenings, including deals and partnerships, and other news in brief: Alnylam, Astrazeneca, Caris, Compugen, Eli Lilly, Medi&Gene, Norgine, Protalix, Roche, Secarna, Vir, Vyne, Yarrow. Read More

Regulatory snapshots, including global drug submissions and approvals, and other regulatory decisions and designations: Antengene, GSK, Sanofi. Read More